Company Overview and News
JAKS Resources Bhd (Sept 20, RM1.01) Maintain buy with a lower target price (TP) of RM1.75: We remain optimistic about JAKS Resources Bhd’s outlook post our recent meeting with management. We expect earnings growth to be stronger in the second half of 2018 (2HFY18), driven by the higher revenue recognition from its Vietnam engineering, procurement, construction and commissioning (EPCC) contract; however, we are cutting our earnings per share (EPS) for FY18 estimate (FY18E) to FY20E by 9.
KUALA LUMPUR (Aug 28): Jaks Resources Bhd’s second quarter net profit soared more than six times to RM12.74 million from RM1.98 million a year earlier, thanks to a RM5.8 million gain from sale of land in Subang Jaya and higher progress billings from its engineering, procurement and construction (EPC) contract in Vietnam.
4723 BSMAF 1818
KUALA LUMPUR (July 31): The FBM KLCI reversed its earlier losses at the midday break today, lifted by select index-linked blue chips, but the broader market sentiment remained tepid, tracking regional markets.
7083 HLFBF 1082 5032 NFLX BATS 4162 3794 9334 6033 7277 2852 PNADF 5225 3301 3867 4723 Q0F IHHHF 6807 PNAGF 1929
KUALA LUMPUR (July 30): Based on corporate announcements and news flow today, companies in focus on Tuesday (July 31) may include: Top Glove Corp Bhd, JAKS Resources Bhd, Star Media Group Bhd, Malaysia Building Society Bhd, Barakah Offshore Petroleum Bhd, Handal Resources Bhd, Fima Corp Bhd, Datasonic Group Bhd, New Hoong Fatt Holdings Bhd, Rev Asia Bhd and Tadmax Resources Bhd
6084 7251 7060 7113 TPGVF 1171 0173 7253 4022 TGLVY 5216 4723 WWDH
KUALA LUMPUR (July 30): JAKS Resources Bhd has been granted an interim injunction from the Federal Court today to restrain the payout of a RM50 million bank guarantee to Star Media Group Bhd.
6084 4723 BSMAF 1818
2018-07-28 thestar.com.my - 1
KUALA LUMPUR: The court has yet again ruled in favour of Star Media Group Bhd paving the way for two financial institutions to release bank guarantees amounting to RM50mil to the media giant.
2018-07-27 theedgemarkets - 1
KUALA LUMPUR (July 27): The Court of Appeal today dismissed the application by JAKS Resources Bhd for an Erinford Injunction to restrain the payout of a RM50 million bank guarantee to Star Media Group Bhd.
6084 4723 BSMAF 1818
KUALA LUMPUR(July 27): Shares of JAKS Resources Bhd fell as much as 8% this morning to RM1.04, in the aftermath of the company’s announcement yesterday that a prominent investor had disposed of some shares as well as ahead of its injunction hearing appeal.
KUALA LUMPUR (July 27): The FBM KLCI was down marginally at mid-morning, tracking losses at regional markets.
9385 GMALF 4065 7113 TPGVF BATS 4162 5202 7123 CIMDF GMALY TGLVY KLKBY 1023 2445 5347 2542 4715 TNABY 4723 2739 TNABF 3719
KUALA LUMPUR (July 25): Based on corporate announcements and news flow today, companies that may be in focus on Thursday (July 26) may include the following: Westports Holdings Bhd, Star Media Group Bhd, JAKS Resources Bhd, Cuscapi Bhd, Uzma Bhd, Marine & General Bhd, Vizione Holdings Bhd, D’nonce Technology Bhd, Capitaland Malaysia Mall Trust, Gadang Holdings Bhd, M-Mode Bhd and Mega First Corporation Bhd.
9261 6084 5180 4723 5246 BSMAF MGFCF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...